ReviewCurrent cancer drug targets2017
HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Sarah L Sammons et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
48 papers cite it
this paperpooled ittrialcites it